Mihaly Hajos
About Mihaly Hajos
Mihály Hajós is the Chief Scientific Officer focused on preclinical research and translational medicine for Alzheimer’s disease, with a background in both academic and industrial drug discovery.
Mihály Hajós Chief Scientific Officer
Mihály Hajós is the Chief Scientific Officer who oversees preclinical research and translational medicine with a specific focus on Alzheimer’s disease. In this role, he is involved in the intricate studies and development phases essential for understanding and combating this neurodegenerative disorder. His work includes overseeing various research teams, setting scientific priorities, and ensuring that scientific discoveries are translated into therapeutic innovations.
Education and Expertise in Pharmacology and Neurophysiology
Mihály Hajós holds a PharmD degree from Szent-Gyorgyi Medical University in Hungary. He furthered his education with a PhD from the University of Gothenburg in Sweden. His educational background provides a solid foundation for his expertise in pharmacology and neurophysiology. His research focuses on biomarkers and their use as translational research tools, exploring their potential roles in diagnosing and understanding neurological conditions.
Academic and Industrial Experience
Throughout his career, Mihály Hajós has held key positions in both academic and industrial settings. He has been associated with prestigious institutions like the University of Oxford, where he contributed to foundational research in drug discovery. In the pharmaceutical industry, he has worked with notable companies such as Pfizer and Biogen, where he played a significant role in developing new therapeutic approaches. Currently, he is also a professor adjunct at Yale University School of Medicine, where he continues to contribute to academic research and education.
Research Contributions to Alzheimer's Disease
Mihály Hajós is deeply involved in research related to Alzheimer's disease, particularly in the area of sensory gamma stimulation. He explores therapeutic applications of this technique as potential treatments for Alzheimer's. One of his research interests includes developing personalized treatments based on the neurophysiological characteristics of patients. He also chairs the Alzheimer’s Association Electrophysiology Professional Interest Area, which involves leading discussions and initiatives on the electrophysiological aspects of Alzheimer's research.
Interests in Biomarkers and Translational Medicine
Mihály Hajós has a keen interest in the use of biomarkers as translational research tools. His work aims to utilize these biological markers to bridge the gap between laboratory research and clinical application, ensuring that scientific discoveries can effectively translate into patient care. His focus on preclinical research helps in understanding the underlying molecular mechanisms of diseases and in identifying potential targets for therapeutic intervention.